Kisunla (donanemab)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Ready

Primary summary from verified readiness

Evidence strength Strong

Decision

Human editorial judgment · 2026-07-23

Proceed with caution

Why: Donanemab has genuine regulatory and trial-level substance (FDA July 2024, EMA Sept 2025, ~48 countries, 35% slowing of decline on iADRS in the low/medium-tau trial population) but carries a fatal-risk boxed warning, an EMA rejection that was only reversed after restricting eligible patients, an NHS funding refusal, and unresolved 2026 meta-analyses questioning clinical significance -- too contested to treat as settled best practice for the class.
Next: Monitor Lilly's multi-year real-world observational cohort (launched Oct 2024, comparing treated patients to usual care) and post-2026 meta-analytic/Cochrane literature for an updated risk-benefit read before citing donanemab's treat-to-target protocol as a template for future amyloid-clearance approvals.

Constraints

No named blocker is present in the current public projection.

Evidence summary

AI-assisted assembly

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Initial public reading